web analytics
10.4 C
Munich
Monday, October 25, 2021

SBFM-PL4; the Swift Run on Sunshine Biopharma, Inc. (OTCMKTS:SBFM)

Sunshine Biopharma, Inc. (OTCMKTS:SBFM) is making a powerful run up the charts on a massive surge of volume in recent days exploding past all previous highs and embarking on a serious blue sky breakout! Microcapdaily has been reporting on SBFM since the stock was well below $0.01 and could not be happier for longs here some of which suffered for years after the intial IPO.

SBFM is getting noticed as the Company develops its flagship coronavirus molecule; SBFM-PL4 in collaboration with the University of Georgia, College of Pharmacy.  Sunshine Biopharma is currently advancing the development of SBFM-PL4 through the in vitro testing stage to be followed by mice studies before entering clinical trials on COVID-19 patients. SBFM started to move last summer after the Company filed a provisional patent application for several molecules which were designed by computer-aided modeling to inhibit the Coronavirus proteases, thus shutting down the ability of the virus to multiply. Since than SBFM has been rapidly developing its covid-19 treatment recently announcing it has received the fourth tranche of funding under the recently announced committed minimum financing of $2,000,000 with RB Capital Partners Inc. This brings the total to $1,050,000 that the Company has received to date under this financing. The proceeds are being used for the ongoing development of the Company’s Coronavirus Treatment on a priority basis and the clinical development of Adva-27a, the Company’s flagship anticancer compound targeted for pancreatic cancer.

Sunshine Biopharma, Inc. (OTCMKTS:SBFM) is hard at work developing its treatment for COVID-19. The Company is also engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.

Microcapdaily first reported on SBFM on April 4, 2015 stated at the time: “SBFM traded for well over $1 in 2011 and was over $0.25 for most of 2012 as many investors put significant money into this stock because they believed in Dr. Steve N. Slilaty and his vision for Adva-27a. This vision never came to fruition however and SBFM collapsed as insiders cashed in their chips and let the stock drift into oblivion decimating the original shareholder’s investment in the Company. The result is a large group of investors who were wiped out by SBFM and are understandably very angry with Dr. Steve N. Slilaty who was recently seen driving about town in his new black BMW M6 convertible. As SBFM hit its lowest point just over a penny Bombaykid stepped in to save the day stating: ”that is not true, i work for lonza in india and sunshine pharma just bought a 10,000square feet facility, i will be working for it sunshine plant in india me very happy. Veri good news come out next week say doct karithe, veri powerful in india, doct karithe veri veri smart. Very very cheap, me buy cheap low, keep high india smart buiness peoples.”

On May 22, 2020, Sunshine Biopharma filed a provisional patent application for several molecules which were designed by computer-aided modeling to inhibit the Coronavirus proteases, thus shutting down the ability of the virus to multiply. Sunshine Biopharma has since completed the synthesis of four such molecules and identified a lead compound, SBFM-PL4. In collaboration with the University of Georgia, College of Pharmacy, the Company is currently advancing the development of SBFM-PL4 through the in vitro testing stage to be followed by mice studies before entering clinical trials on COVID-19 patients. Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 1.9 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest replication of the virus in people who have contracted the illness.

To Find out the inside Scoop on SBFM Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

SBFMOn June 3 SBFM filed a patent application in the United States for a new treatment for Coronavirus infections, including COVID-19. Sunshine’s patent application covers composition subject matter pertaining to small molecules for inhibition of the main Coronavirus protease (Mpro), an enzyme that is essential for viral replication. The small molecules covered by the patent application were computer modelled and designed by Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. The patent application has a priority date of May 22, 2020.

Late last year SBFM entered into a $2 million friendly financing agreement with RB Capital. The proceeds are being used for development of the Company’s recently announced Coronavirus treatment on a priority basis and the clinical development of Adva-27a, the Company’s flagship anticancer compound targeted for pancreatic cancer. Last week the Company announced it has received the fourth tranche of funding under the recently announced committed minimum financing of $2,000,000 with RB Capital Partners Inc. This brings the total to $1,050,000 that the Company has received to date under this financing. The proceeds will be used for the ongoing development of the Company’s Coronavirus Treatment on a priority basis and the clinical development of Adva-27a, the Company’s flagship anticancer compound targeted for pancreatic cancer.

Sunshine Biopharma Inc. CFO, Camille Sebaaly stated, “As a company, we continue to forge forward in our development of a COVID treatment and our anticancer compounds. This investment capital has been integral to our progress in each of these sectors.”

Brett Rosen and Deborah Braun of RB Capital Partners Inc. stated, “We are very impressed with the Sunshine leadership team and their commitment to developing critical life-saving medical treatments. Our investment money has been met with ongoing milestones and we are pleased to be considered a long-term funding partner of the Company. We are looking forward to a potential up-list to the Nasdaq in the future.”

For More on SBFM Subscribe Right Now!

SBFM is getting noticed as the Company develops its flagship coronavirus molecule; SBFM-PL4 in collaboration with the University of Georgia, College of Pharmacy.  Sunshine Biopharma is currently advancing the development of SBFM-PL4 through the in vitro testing stage to be followed by mice studies before entering clinical trials on COVID-19 patients. SBFM started to move last summer after the Company filed a provisional patent application for several molecules which were designed by computer-aided modeling to inhibit the Coronavirus proteases, thus shutting down the ability of the virus to multiply. Since than the Company has been rapidly developing its covid-19 treatment recently announcing it has received the fourth tranche of funding under the recently announced committed minimum financing of $2,000,000 with RB Capital Partners Inc. This brings the total to $1,050,000 that the Company has received to date under this financing. The proceeds are being used for the ongoing development of the Company’s Coronavirus Treatment on a priority basis and the clinical development of Adva-27a, the Company’s flagship anticancer compound targeted for pancreatic cancer. The Company is led by CEO Dr. Slilaty is an accomplished scientist and a highly skilled business executive. He received his Bachelor of Science degree in Genetics and Biochemistry from Cornell University and his Ph.D. in Molecular Biology & Biochemistry from the University of Arizona. Dr. Slilaty is a leader in the bioscience industry and is referenced in editorials, reviews and textbooks. His extensive contributions to science included the discovery of a new class of enzymes (IUBMB Enzyme: EC 3.4.21.88) and the development of key technology for the Human Genome Project (TrueBlue Cloning System). With a passion for medicine, he founded three biotech companies and took one public. The company he took public, Genomics One Corporation reached $1 billion market cap. Microcapdaily was reporting on SBFM when the stock was trading less then $0.01.  We will be updating on SBFM when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with SBFM.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in SBFM either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.